Healthcare Stocks in Thursday's Intraday Session: APM, AEMD, PTIX, THAR, CUPR, IMRX, MODV, ZYBT, LIMN, NVNO, ISPC, and IVVD.

Several health care stocks moved significantly in Thursday's intraday session, with Aptorum Group APM stock rising 163.0% to $3.34, Aethlon Medical AEMD shares up 114.32% to $2.38, and Protagenic Therapeutics PTIX shares up 100.42% to $4.57. Meanwhile, ModivCare MODV shares declined 65.4% to $0.64, Zhengye Biotechnology ZYBT stock fell 29.83% to $6.66, and Liminatus Pharma LIMN stock decreased 17.37% to $2.76.

Several healthcare stocks experienced significant intraday movements on Thursday, with notable gains and losses. Aptorum Group's APM stock surged 163.0% to $3.34, while Aethlon Medical's AEMD shares rose 114.32% to $2.38. Protagenic Therapeutics' PTIX shares also saw a substantial increase of 100.42% to $4.57. Meanwhile, ModivCare's MODV shares declined 65.4% to $0.64, Zhengye Biotechnology's ZYBT stock fell 29.83% to $6.66, and Liminatus Pharma's LIMN stock decreased 17.37% to $2.76.

Aptorum Group (APM)
Aptorum Group's stock experienced a robust rally, with a 168.16 million share volume compared to the average volume of 3.25 million. The company's merger partner, DiamiR Biosciences Corp., received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH) [1]. This milestone allows DiamiR to offer its validated APOE Genotyping molecular testing in various biological samples through its CLIA certified, CAP accredited clinical laboratory. The merger between Aptorum and DiamiR Biosciences is expected to close in the fourth quarter of 2025, with the combined company remaining listed on the Nasdaq Stock Market [1].

Aethlon Medical (AEMD)
Aethlon Medical's stock surged 49.49% intraday to $1.6593, despite a 39.3% Q1 revenue drop and operating losses. The company announced a 31.6% operating expense reduction and the completion of its Australian Hemopurifier cancer trial cohort. Additionally, Aethlon Medical filed an S-1 registration for 1.55 million shares and 6.5% cash fees, sparking speculative buying. The stock's technical indicators suggest extreme short-term overextension, with the RSI at 43.55 indicating oversold conditions [3]. However, the stock's 1.795 price—far above all moving averages and Bollinger Bands—indicates a potential correction.

Protagenic Therapeutics (PTIX)
Protagenic Therapeutics' stock experienced a staggering 105.70% intraday price jump, with a trading volume of 151,338,495 shares. The sudden movement, in the absence of significant new fundamental announcements, suggests a sharp breakout or reaction to external factors such as a viral message or a targeted strategy [5]. The stock's low liquidity and thin order book may have contributed to the dramatic price spike.

ModivCare (MODV)
ModivCare's stock declined 65.4% to $0.64, marking a significant drop in value. The company's stock performance may be influenced by broader market sentiment or specific industry developments, but no specific reasons for the decline were mentioned in the provided source materials.

Zhengye Biotechnology (ZYBT)
Zhengye Biotechnology's stock fell 29.83% to $6.66, indicating a notable decrease in value. The company's stock performance may be influenced by various factors, including market sentiment, industry developments, or specific company news.

Liminatus Pharma (LIMN)
Liminatus Pharma's stock decreased 17.37% to $2.76, reflecting a significant drop in value. The company's stock performance may be influenced by various factors, including market sentiment, industry developments, or specific company news.

References:
[1] https://www.benzinga.com/news/health-care/25/08/47263106/why-is-nano-cap-aptorum-stock-rallying-on-thursday
[2] https://ca.finance.yahoo.com/quote/AEMD/
[3] https://www.ainvest.com/news/aethlon-medical-53-intraday-surge-volatile-gamble-exosome-patents-financial-peril-2508/
[4] https://ca.finance.yahoo.com/quote/PTIX/
[5] https://www.ainvest.com/news/ptix-protagenic-skyrockets-105-intraday-surge-unusual-move-2508/